Bruce Carter is chairman of the board. He headed ZGEN through turbulent times and was able to salvage value for investors when BMY bought them out after their clinical drug bombed. I wouldn't be surprised if he pushes to offload all the clinical assets for whatever they can get, probably RSV has value but little else, and he gets the company more focused which frankly should get them to at least close to cash value minus restructuring costs/ finishing spend on RSV. They can probably generate 100M for their royalty interest and have a 30M refund due from the IRS, so doing the math, figuring an additional 50M to wind down RSV program etc., gets us to double digits pretty easily. Assuming they are 80+% enrolled in HR I would even unblind that trial early - it's pretty important to have that data to know the value of the RSV assets
Market Data 
Markets 
AI
